Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • Fluoxetine
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Fluoxetine

THERAPEUTICS

Brands

  • Prozac
  • Prozac weekly
  • Sarafem
  • see index for additional brand names

Generic?

  • Yes

Class

  • SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant, but it is not just an antidepressant

Commonly Prescribed for

  • (bold for FDA approved)
  • Major depressive disorder (ages 8 and older)
  • Obsessive-compulsive disorder (OCD)(ages 7 and older)
  • Premenstrual dysphoric disorder (PMDD)
  • Bulimia nervosa
  • Panic disorder
  • Bipolar depression [in combination with olanzapine (Symbyax)]
  • Treatment-resistant depression [in combination with olanzapine (Symbyax)]
  • Social anxiety disorder (social phobia)
  • Posttraumatic stress disorder (PTSD)

How the Drug Works

  • Boosts neurotransmitter serotonin
  • Blocks serotonin reuptake pump (serotonin transporter)
  • Desensitizes serotonin receptors, especially serotonin 1A receptors
  • Presumably increases serotonergic neurotransmission
  • Fluoxetine also has antagonist properties at 5HT2C receptors, which could increase norepinephrine and dopamine neurotransmission

How Long Until It Works

  • Some patients may experience increased energy or activation early after initiation of treatment
  • Onset of therapeutic actions usually not immediate, but often delayed 2-4 weeks
  • If it is not working within 6-8 weeks, it may require a dosage increase or it may not work at all
  • May continue to work for many years to prevent relapse of symptoms

If It Works

  • The goal of treatment is complete remission of current symptoms as well as prevention of future relapses
  • Treatment most often reduces or even eliminates symptoms, but not a cure since symptoms can recur after medicine stopped
  • Continue treatment until all symptoms are gone (remission) or significantly reduced (e.g., OCD, PTSD)
  • Once symptoms are gone, continue treating for 1 year for the first episode of depression
  • For second and subsequent episodes of depression, treatment may need to be indefinite
  • For anxiety disorders and bulimia, treatment may also need to be indefinite

If It Doesn’t Work

  • Many patients have only a partial response where some symptoms are improved but others persist (especially insomnia, fatigue, and problems concentrating in depression)
  • Other patients may be nonresponders, sometimes called treatment-resistant or treatment-refractory
  • Some patients who have an initial response may relapse even though they continue treatment, sometimes called “poop-out”
  • Consider increasing dose, switching to another agent or adding an appropriate augmenting agent
  • Consider psychotherapy
  • Consider evaluation for another diagnosis or for a comorbid condition (e.g., medical illness, substance abuse, etc.)
  • Some patients may experience apparent lack of consistent efficacy due to activation of latent or underlying bipolar disorder, and require antidepressant discontinuation and a switch to a mood stabilizer

Best Augmenting Combos for Partial Response or Treatment Resistance

  • Trazodone, especially for insomnia
  • Bupropion, mirtazapine, reboxetine, or atomoxetine (add with caution and at lower doses since fluoxetine could theoretically raise atomoxetine levels); use combinations of antidepressants with caution as this may activate bipolar disorder and suicidal ideation
  • Modafinil, especially for fatigue, sleepiness, and lack of concentration
  • Mood stabilizers or atypical antipsychotics for bipolar depression, psychotic depression, treatment-resistant depression, or treatment-resistant anxiety disorders
  • Fluoxetine has been specifically studied in combination with olanzapine (olanzapine-fluoxetine combination) with excellent results for bipolar depression, treatment-resistant unipolar depression, and psychotic depression
  • Benzodiazepines
  • If all else fails for anxiety disorders, consider gabapentin or tiagabine
  • Hypnotics for insomnia
  • Classically, lithium, buspirone, or thyroid hormone

Tests

  • None for healthy individuals
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us